The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey
- PMID: 37909013
- PMCID: PMC10614292
- DOI: 10.3389/fonc.2023.1272561
The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey
Abstract
The journey of metastatic colorectal cancer patients is complex and challenging, requiring coordination and collaboration between multiple healthcare providers. Understanding patients' needs, fears, feelings, concerns, and behaviors is essential for providing individualized patient-centered care. In recent years, mCRC patients have experienced improvements in clinical outcomes, from 16 months of overall survival to 32 months, thanks to research. However, there is still room for improvement, and integrating clinical and translational research into routine practice can help patients benefit from treatments and techniques that would not be an option. In the Journey of mCRC patients, living well with cancer and quality of life becomes a priority given the outcomes of the disease. Patient reported outcomes (PRO) and Patient Reported Outcome Measures (PROMs) are becoming therefore new estimands in Oncology. Patient advocates represent important figures in this process by prioritizing issues and research questions; evaluating research designs and the performance of the research; the analysis and interpretation of data; and how results are disseminated. Multidisciplinary Tumor Boards and shared decision-making is essential for designing treatment strategies for individual patients. Quality of Life is often prioritized only when it comes to refractory advanced disease and end-of-life care, but it has to be integrated from the beginning, as the emotional impact of diagnosis leads to a vulnerable situation where patients' needs and preferences can be easily overseen. First-line treatment will be chosen among more treatment options than subsequent lines, with longer progression-free survival and a bigger impact on the outcomes. Practicing patient-centered care and optimizing first-line treatment for colorectal cancer patients requires a comprehensive understanding of patient experience and treatment outcomes, which can guide clinical practice and inform regulatory decisions for the benefit of patients.
Keywords: colorectal cancer; patient journey; patient reported outcome measures; patient reported outcomes; quality of life.
Copyright © 2023 Rodriguez Castells, Baraibar, Ros, Saoudi, Salvà, García, Alcaraz, Tabernero and Élez.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432. JBI Libr Syst Rev. 2012. PMID: 27820528
-
The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.JBI Database System Rev Implement Rep. 2015 Jan;13(1):76-87. doi: 10.11124/jbisrir-2015-1072. JBI Database System Rev Implement Rep. 2015. PMID: 26447009
-
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review.Pharmaceut Med. 2025 May;39(3):171-182. doi: 10.1007/s40290-025-00568-9. Epub 2025 May 14. Pharmaceut Med. 2025. PMID: 40369361 Free PMC article. Review.
-
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.JMIR Cancer. 2022 Sep 22;8(3):e39068. doi: 10.2196/39068. JMIR Cancer. 2022. PMID: 36136395 Free PMC article. Review.
Cited by
-
Precision medicine in colorectal cancer: genomics profiling and targeted treatment.Front Pharmacol. 2025 Feb 27;16:1532971. doi: 10.3389/fphar.2025.1532971. eCollection 2025. Front Pharmacol. 2025. PMID: 40083375 Free PMC article. Review.
-
Assessment of the quality of life in metastatic colorectal cancer patients with KRAS gene mutant: a case-control study.BMC Cancer. 2025 Jan 28;25(1):158. doi: 10.1186/s12885-025-13538-w. BMC Cancer. 2025. PMID: 39871164 Free PMC article.
-
High Expression Level of TRIP6 is Correlated with Poor Prognosis in Colorectal Cancer and Promotes Tumor Cell Proliferation and Migration.Biochem Genet. 2025 Feb;63(1):261-280. doi: 10.1007/s10528-024-10711-x. Epub 2024 Mar 2. Biochem Genet. 2025. PMID: 38430448
-
AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation.Cancer Chemother Pharmacol. 2024 Sep;94(3):373-385. doi: 10.1007/s00280-024-04685-1. Epub 2024 Jun 18. Cancer Chemother Pharmacol. 2024. PMID: 38890190
References
-
- Maravic Z, Rawicka I, Benedict A, Wyrwicz L, Horvath A, Fotaki V, et al. . A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. ESMO Open (2020) 5(5):e000850. doi: 10.1136/esmoopen-2020-000850 - DOI - PMC - PubMed
-
- Lowes M, Kleiss M, Lueck R, Detken S, Koenig A, Nietert M, et al. . The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer. Int J Colorectal Dis (2017) 32(10):1463–9. doi: 10.1007/s00384-017-2871-z - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources